论文部分内容阅读
目的 :观察羟基喜树碱 (HCPT)联合化疗治疗中晚期非小细胞肺癌 (NSCLC)的疗效及其不良反应。方法 :随机将 6 2例经病理证实为NSCLC的患者分为研究组 31例 ,接受CAP方案化疗 ,同时加用羟基喜树碱10mg/d静滴 ;对照组 31例 ,单纯接受CAP方案化疗。结果 :研究组鳞癌的治疗有效率为 5 2 .6 4 % ,腺癌的治疗有效率为 5 0 .0 0 % ,与对照组相比有显著性差异 (P <0 .0 5 ) ;而研究组的不良反应明显小于对照组 ,差异有显著性 (P <0 .0 5 )。结论 :羟基喜树碱联合化疗能提高中晚期非小细胞肺癌的疗效 ,毒副反应小 ,耐受性好。
Objective: To observe the efficacy and adverse reactions of hydroxycamptothecin (HCPT) combined with chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). Methods: Sixty-two patients with NSCLC confirmed by pathology were randomly divided into study group (n = 31) and receive CAP regimen plus hydroxycamptothecin (10 mg / d) intravenously. The control group (n = 31) received CAP regimen alone. Results: The effective rate of treatment of squamous cell carcinoma in study group was 52.44% and that of adenocarcinoma was 50.0%, which was significantly different from that in control group (P <0.05). The adverse reactions in the study group were significantly less than those in the control group (P <0.05). Conclusion: Hydroxycamptothecin combined with chemotherapy can improve the curative effect of advanced non-small cell lung cancer with little side effects and good tolerance.